Biomerica, Inc. (OTCMKTS:BMRA) announced its quarterly earnings data on Monday, October 16th. The company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01, Bloomberg Earnings reports. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $1.52 million. Biomerica had a negative net margin of 23.86% and a negative return on equity of 29.80%.
Biomerica (BMRA) opened at 2.80 on Friday. The firm’s market cap is $23.86 million. The company has a 50-day moving average of $2.80 and a 200 day moving average of $2.64. Biomerica has a 52-week low of $1.53 and a 52-week high of $2.99.
Separately, ValuEngine lowered shares of Biomerica from a “hold” rating to a “sell” rating in a research report on Friday, August 11th.
TRADEMARK VIOLATION WARNING: “Biomerica, Inc. (OTCMKTS:BMRA) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/biomerica-inc-bmra-releases-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.
Biomerica Company Profile
Biomerica, Inc is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores).
Receive News & Ratings for Biomerica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica Inc. and related companies with MarketBeat.com's FREE daily email newsletter.